Commercial
  
  
  
  
  
  
  
  
  
  
  
MPattachmentdataPub
  
ad72e765-70b2-46fc-a65d-4160b459de88.aspx
  
Pegfilgrastim(Neulasta®)andrelatedbiosimilars08.01.32g08.01.32gPharmacy (08)Pegfilgrastim (Neulasta®) and related biosimilarsad72e765-70b2-46fc-a65d-4160b459de883839Pegfilgrastim (Neulasta®) and related biosimilars08.01.3211/9/2021 11:00 AM
{"3840": {"Id":3840,"MPAttachmentLetter":"A","Title":"EXAMPLES OF DISEASE SETTINGS AND CHEMOTHERAPY REGIMENS WITH A HIGH (>20%) OR INTERMEDIATE (10-20%) RISK FOR FEBRILE NEUTROPENIA","MPPolicyAttachmentInternalSourceId":5725,"PolicyAttachmentPageName":"a6eab59d-f351-4044-901f-06658faafb6c"},}
2/7/2022
85f3b0fc-77f5-4f84-a19c-04db9cba2fcc.aspx
  
ModifiersforAssistant-at-SurgeryServices:80,81,82,andAS00.10.18r00.10.18rAdministrative (00)Modifiers for Assistant-at-Surgery Services: 80, 81, 82, and AS85f3b0fc-77f5-4f84-a19c-04db9cba2fcc3745Modifiers for Assistant-at-Surgery Services: 80, 81, 82, and AS00.10.1811/5/2021 2:00 PM
2/14/2022
baf8fae0-2c70-43bc-85b9-3caed8246664.aspx
  
InfliximabandRelatedBiosimilars08.00.34q08.00.34qPharmacy (08)Infliximab and Related Biosimilarsbaf8fae0-2c70-43bc-85b9-3caed82466643988Infliximab and Related Biosimilars08.00.341/14/2022 10:00 AM
{"3989": {"Id":3989,"MPAttachmentLetter":"B","Title":"ICD-10-CM Codes and Narratives","MPPolicyAttachmentInternalSourceId":6112,"PolicyAttachmentPageName":"46fd6a28-b3cf-44ad-82cf-9061009eff15"},"3990": {"Id":3990,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements for Infliximab and Related Biosimilars","MPPolicyAttachmentInternalSourceId":6113,"PolicyAttachmentPageName":"82850786-a2d6-4e91-a92d-380f3ed7931b"},}
2/15/2022
f8f6a0ce-087c-4425-a851-754fae5336e5.aspx
  
Electromyography(EMG)Studies:NeedleEMG,SurfaceEMG(SEMG)07.03.09s07.03.09sMedicine (07)Electromyography (EMG) Studies: Needle EMG, Surface EMG (SEMG)f8f6a0ce-087c-4425-a851-754fae5336e53857Electromyography (EMG) Studies: Needle EMG, Surface EMG (SEMG)07.03.0912/20/2021 12:00 PM
{"3858": {"Id":3858,"MPAttachmentLetter":"A","Title":"Recommended Guidelines for Electrodiagnostic Studies","MPPolicyAttachmentInternalSourceId":5970,"PolicyAttachmentPageName":"aa854370-b52c-4e87-97a8-685372ba3cdb"},"3859": {"Id":3859,"MPAttachmentLetter":"D","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5971,"PolicyAttachmentPageName":"112acff1-3121-4d19-a59f-a6f773864a9b"},"3860": {"Id":3860,"MPAttachmentLetter":"F","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5972,"PolicyAttachmentPageName":"e7389844-1cab-4a41-ac14-b8e4545f9f35"},"3861": {"Id":3861,"MPAttachmentLetter":"B","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5973,"PolicyAttachmentPageName":"27c85dd3-ce1f-4a03-b845-569ee604353d"},"3862": {"Id":3862,"MPAttachmentLetter":"G","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5974,"PolicyAttachmentPageName":"e8d48a98-d055-403b-b6fe-f20e639301e3"},"3863": {"Id":3863,"MPAttachmentLetter":"C","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5975,"PolicyAttachmentPageName":"2f1e6486-4094-4f62-84e8-bfcb088c96d2"},"3864": {"Id":3864,"MPAttachmentLetter":"K","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5976,"PolicyAttachmentPageName":"3d74a3c8-2c52-422d-9f07-abd3d140f080"},"3865": {"Id":3865,"MPAttachmentLetter":"I","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5977,"PolicyAttachmentPageName":"a5e54d8e-eb55-4f45-88f2-e8d2a557d805"},"3866": {"Id":3866,"MPAttachmentLetter":"E","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5978,"PolicyAttachmentPageName":"8c6b1ba8-6dce-4abb-ac20-f75244a211c8"},"3867": {"Id":3867,"MPAttachmentLetter":"J","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5979,"PolicyAttachmentPageName":"b5b97d86-425d-4f9f-9474-ebf9e5cd0b92"},"3868": {"Id":3868,"MPAttachmentLetter":"H","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5980,"PolicyAttachmentPageName":"3c716980-ab5b-44e4-bd23-890f66b171bc"},}
3/21/2022
1c1f7a5f-3dfa-4f7c-a7c5-3ac09e9faae4.aspx
  
NerveConductionStudies(NCS)andRelatedElectrodiagnosticStudies07.03.18r07.03.18rMedicine (07)Nerve Conduction Studies (NCS) and Related Electrodiagnostic Studies1c1f7a5f-3dfa-4f7c-a7c5-3ac09e9faae43869Nerve Conduction Studies (NCS) and Related Electrodiagnostic Studies07.03.1812/20/2021 12:00 PM
{"3870": {"Id":3870,"MPAttachmentLetter":"A","Title":"Recommended Guidelines for Electrodiagnostic Studies","MPPolicyAttachmentInternalSourceId":5992,"PolicyAttachmentPageName":"c37d72b4-40ea-4ef0-8b6c-b6ad537a90d4"},"3871": {"Id":3871,"MPAttachmentLetter":"F","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5993,"PolicyAttachmentPageName":"44c8b4ac-dce6-4468-bafe-5b71875a8860"},"3872": {"Id":3872,"MPAttachmentLetter":"C","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5994,"PolicyAttachmentPageName":"f2dd47b8-e2c9-48d1-b59c-3c8760788cd2"},"3873": {"Id":3873,"MPAttachmentLetter":"D","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5995,"PolicyAttachmentPageName":"209b6952-b9bb-485f-b2a1-ec4bf1e7cba0"},"3874": {"Id":3874,"MPAttachmentLetter":"E","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5996,"PolicyAttachmentPageName":"458f1874-517a-48a2-8c4e-a37f0e3f92e4"},"3875": {"Id":3875,"MPAttachmentLetter":"B","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5997,"PolicyAttachmentPageName":"5d534d1b-869e-4b73-9d7e-75e6aa5070e6"},"3876": {"Id":3876,"MPAttachmentLetter":"K","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5998,"PolicyAttachmentPageName":"dd576c53-c9bc-4b64-a727-6ca50b7c05df"},"3877": {"Id":3877,"MPAttachmentLetter":"J","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5999,"PolicyAttachmentPageName":"2bfcbd0c-9363-45f2-ba90-72f72de06116"},"3878": {"Id":3878,"MPAttachmentLetter":"I","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":6000,"PolicyAttachmentPageName":"5092dc07-7e00-4cf2-a6a5-dc19dfa91643"},"3879": {"Id":3879,"MPAttachmentLetter":"H","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":6001,"PolicyAttachmentPageName":"ab013d66-308d-487f-b1e2-021e15abb979"},"3880": {"Id":3880,"MPAttachmentLetter":"G","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":6002,"PolicyAttachmentPageName":"5a668dcd-c2c9-4d7a-9106-ed1ce4ec5f4c"},}
3/21/2022
aeeb63b5-3df0-48f6-88b1-34200c4ebdc8.aspx
  
Pertuzumab,Trastuzumab,andHyaluronidase-zzxf(Phesgo®)08.01.72a08.01.72aPharmacy (08)Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo®)aeeb63b5-3df0-48f6-88b1-34200c4ebdc83887Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo®)08.01.7212/21/2021 7:00 AM
3/21/2022
5f331758-7796-43ae-a766-3d54fe77664a.aspx
  
pegfilgrastim(Neulasta®)andrelatedbiosimilars08.01.32h08.01.32hPharmacy (08)pegfilgrastim (Neulasta®) and related biosimilars5f331758-7796-43ae-a766-3d54fe77664a3897pegfilgrastim (Neulasta®) and related biosimilars08.01.3212/31/2021 9:00 AM
{"3898": {"Id":3898,"MPAttachmentLetter":"A","Title":"EXAMPLES OF DISEASE SETTINGS AND CHEMOTHERAPY REGIMENS WITH A HIGH (>20%) OR INTERMEDIATE (10-20%) RISK FOR FEBRILE NEUTROPENIA","MPPolicyAttachmentInternalSourceId":6058,"PolicyAttachmentPageName":"9151992b-8300-4f11-a49e-444181230040"},}
4/1/2022
07dd187e-4940-4468-a4e4-c23707a35f67.aspx
  
Rituximab(Rituxan®)InfusionandRelatedBiosimilars,andRituximab/HyaluronidaseHumanforSubcutaneousInjection(RituxanHycela®)08.00.50z08.00.50zPharmacy (08)Rituximab (Rituxan®) Infusion and Related Biosimilars, and Rituximab/Hyaluronidase Human for Subcutaneous Injection (Rituxan Hycela®)07dd187e-4940-4468-a4e4-c23707a35f673899Rituximab (Rituxan®) Infusion and Related Biosimilars, and Rituximab/Hyaluronidase Human for Subcutaneous Injection (Rituxan Hycela®)08.00.5012/31/2021 9:00 AM
{"3900": {"Id":3900,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements For Rituximab (Rituxan®) infusion and related biosimilars, and rituximab/hyaluronidase human for subcutaneous injection (Rituxan Hycela®)","MPPolicyAttachmentInternalSourceId":6060,"PolicyAttachmentPageName":"3ce263eb-7f76-4457-8e5a-df47d9fff133"},"3901": {"Id":3901,"MPAttachmentLetter":"B","Title":"ICD-10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":6061,"PolicyAttachmentPageName":"b6443242-52e8-4c8b-b76e-87c393f173a1"},}
4/1/2022
30aa5c8c-3774-4f2f-81c6-7b02c2d236e4.aspx
  
IntravenousKetamine(Ketalar®)andIntranasalEsketamine(Spravato®)08.01.8008.01.80Pharmacy (08)Intravenous Ketamine (Ketalar®) and Intranasal Esketamine (Spravato®)30aa5c8c-3774-4f2f-81c6-7b02c2d236e43971Intravenous Ketamine (Ketalar®) and Intranasal Esketamine (Spravato®)08.01.801/4/2022 2:00 PM
4/4/2022